BILLIONTOONE INC CL A
BLLNNASDAQTrading Snapshot
- Day Range
- $558.15 – $564.05
- 52-Week Range
- $61.96 – $150.44
- Volume
- $2.42B
- Avg Volume
- $1.90B
- Shares Outstanding
- 46.0M
- Next Earnings
- Nov 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $305M
- Last Q Revenue
- $109M
- P/E Ratio
- 178.4
- P/S Ratio
- 14.2x
- EPS (TTM)
- $0.72
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.4%
Why Investors Own BLLN
- ✓High-growth profile — revenue up +23.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BILLIONTOONE INC CL A
BLLN
StockOtter · stockotter.spaceAbout BILLIONTOONE INC CL A
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
BILLIONTOONE INC CL A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift BLLN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BILLIONTOONE INC CL A announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.